Oragenics (OGEN) Stock Price, News & Analysis

Company Overview

Oragenics, Inc. is a clinical-stage biotechnology company focused on the research and development of novel anti-infective therapeutics targeting oral and mucosal diseases. Headquartered in Tampa, Florida, the company leverages proprietary technologies to address unmet needs in dental and oral healthcare, with an emphasis on innovative treatments that can improve patient outcomes and reduce reliance on traditional antibiotics.

The company’s lead product candidate, Oraprev™, is being developed as a pre-procedural rinse designed to reduce oral microbial load prior to dental procedures. In addition to its dental portfolio, Oragenics is advancing Ogi-04™, a therapeutic candidate for the prevention and treatment of oral mucositis, a common and painful side effect of cancer therapy. Oragenics’ research pipeline also includes earlier-stage programs aimed at broad-spectrum anti-infective applications.

Founded in 1996, Oragenics has built a foundation of proprietary peptide and gene-based platforms that support its drug discovery and development efforts. The company operates primarily in the United States but seeks to establish strategic collaborations to extend its reach into additional markets. Oragenics is listed on the New York Stock Exchange under the ticker symbol OGEN.

Oragenics is led by President and Chief Executive Officer Todd Korth, whose leadership and financial expertise have guided the company’s strategic direction and operational execution. The management team combines scientific experience with regulatory and commercial know-how to advance the company’s clinical programs toward potential commercialization.

Key Stats

• Today's Range: $0.56 to $0.63
• 50-Day Range: $0.50 to $0.98
• 52-Week Range: $0.50 to $9.60
• Volume: 44,782 shs
• Average Volume: 381,561 shs
• Market Capitalization: $2.60 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Oragenics Stock Analysis - MarketRank™

Oragenics scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Oragenics.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Oragenics is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Oragenics is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Oragenics has a P/B Ratio of 0.29. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.55% of the float of Oragenics has been sold short.

Short Interest Ratio / Days to Cover

Oragenics has a short interest ratio ("days to cover") of 11.06, which indicates bearish sentiment.

Change versus previous month

Short interest in Oragenics has recently decreased by 2.78%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Oragenics does not currently pay a dividend.

Dividend Growth

Oragenics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.46

News Sentiment

Oragenics has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Oragenics this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Oragenics insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.10% of the stock of Oragenics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

18.71% of the stock of Oragenics is held by institutions.

Company Calendar

• Last Earnings: 5/08/2026
• Today: 5/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSEAMERICAN
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSEAMERICAN:OGEN
• Previous Symbol: NYSE:OGEN
• CIK: 1174940
• Web: www.oragenics.com
• Phone: 813-286-7900
• Fax: 813-286-7904
• Employees: 5
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($21.42)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$9.84 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -184.42%
• Return on Assets: -118.32%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.64
• Quick Ratio: 5.64

Sales & Book Value

• Annual Sales: $40 thousand
• Price / Sales: 64.88
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.94 per share
• Price / Book: 0.31

Miscellaneous

• Outstanding Shares: 4,340,000
• Free Float: 3,898,000
• Market Cap: $2.60 million
• Optionable: N/A
• Beta: 1.26